• Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections 

      Chemaitelly, Hiam; Ayoub, Houssein H.; AlMukdad, Sawsan; Faust, Jeremy S.; Tang, Patrick; ... more authors (2023 , Article)
      In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains.1 We estimated this vaccine’s effectiveness ...
    • Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant 

      Butt, A.A.; Butt, Adeel A.; Dargham, Soha R.; Loka, Srusvin; Shaik, Riyazuddin M.; ... more authors ( NLM (Medline) , 2022 , Article)
      SHORT SUMMARY: Severe acute respiratory syndrome coronavirus 2 infection from the Omicron variant in children/adolescents is less severe than infection from the Delta variant. Those 6 to <18 years also have less severe ...
    • Covid-19 Vaccine Protection among Children and Adolescents in Qatar. 

      Chemaitelly, Hiam; AlMukdad, Sawsan; Ayoub, Houssein H; Altarawneh, Heba N; Coyle, Peter; ... more authors ( Massachusetts Medical Society , 2022 , Article)
      The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses. We assessed the real-world ...
    • Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease 

      Bansal, Devendra; Abdulmajeed, Jazeel; Al-Shamali, Maha H.M.A.; Albayat, Soha S.A.; Himatt, Sayed M.; ... more authors ( MDPI , 2022 , Article)
      Waning immunity following administration of mRNA-based COVID-19 vaccines remains a concern for many health systems. We undertook a study to determine if recent reports of waning for severe disease could have been attributed ...
    • Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. 

      Abu-Raddad, Laith J; Chemaitelly, Hiam; Ayoub, Houssein H; AlMukdad, Sawsan; Yassine, Hadi M; ... more authors ( Massachusetts Medical Society , 2022 , Article)
      Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited ...
    • Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. 

      Altarawneh, Heba N; Chemaitelly, Hiam; Ayoub, Houssein H; Tang, Patrick; Hasan, Mohammad R; ... more authors ( Massachusetts Medical Society , 2022 , Article)
      The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) ...
    • Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2 

      Chemaitelly, Hiam; Ayoub, Houssein H.; Tang, Patrick; Hasan, Mohammad R.; Coyle, Peter; ... more authors ( Massachusetts Medical Society , 2022 , Other)
      More than 2 years into the coronavirus disease 2019 (Covid-19) pandemic, the global population carries heterogeneous immune histories derived from various exposures to infection, viral variants, and vaccination.1 Evidence ...
    • Protection against Reinfection with the Omicron BA.2.75 Subvariant 

      Chemaitelly, Hiam; Tang, Patrick; Coyle, Peter; Yassine, Hadi M.; Al-Khatib, Hebah A.; ... more authors ( Massachusetts Medical Society , 2023 , Other)
      The BA.2.75 sublineage of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may escape neutralizing antibodies. The BA.2.75 sublineage (primarily the BA.2.75.2 subvariant) ...
    • Protection against the omicron variant from previous SARS-CoV-2 infection 

      Altarawneh, Heba N.; Chemaitelly, Hiam; Hasan, Mohammad R.; Ayoub, Houssein H.; Qassim, Suelen; ... more authors ( Massachusetts Medical Society , 2022 , Other)
      Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha),1,2 B.1.351 (beta),1 and B.1.617.2 (delta)3 variants. However, the ...
    • Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. 

      Chemaitelly, Hiam; Tang, Patrick; Hasan, Mohammad R; AlMukdad, Sawsan; Yassine, Hadi M; ... more authors ( Massachusetts Medical Society , 2021 , Article)
      Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer-BioNTech) vaccine ...